The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Phase I Study of Decitabine Alone or in Combination With Valproic Acid in Acute Myeloid Leukemia
Abstract
Purpose: To determine an optimal biologic dose (OBD) of decitabine as a single agent and then the maximum-tolerated dose (MTD) of valproic acid (VA) combined with decitabine in acute myeloid leukemia (AML). Patients and Methods: Twenty-five patients (median age, 70 years) were enrolled; 12 were untreated and 13 had relapsed AML. To determine an OBD (based on a gene re-expression end point), 14 patients received decitabine alone for 10 days. To determine the MTD, 11 patients received decitabine (at OBD, days 1 through 10) plus dose-escalating VA (days 5 through 21). Results: The OBD of decitabine was 20 mg/m 2/d intravenously, with limited nonhematologic toxicity. In patients treated with decitabine plus VA, dose-limiting encephalopathy occurred in two of two patients at VA 25 mg/kg/d and one of six patients at VA 20 mg/kg/d. Drug-induced re-expression of estrogen receptor (ER) was associated with clinical response (P ≤ .05). ER promoter demethylation, global DNA hypomethylation, depletion of DNA methyltransferase enzyme, and histone hyperacetylation were also observed. In an intent-to-treat analysis, the response rate was 44% (11 of 25). Of 21 assessable patients, 11 (52%) responded: four with morphologic and cytogenetic complete remission (CR; each had complex karyotype), four with incomplete CR, and three with partial remission. In untreated AML, four of nine assessable patients achieved CR. Clinical responses appeared similar for decitabine alone or with VA. Conclusion: Low-dose decitabine was safe and showed encouraging clinical and biologic activity in AML, but the addition of VA led to encephalopathy at relatively low doses. On the basis of these results, additional studies of decitabine (20 mg/m 2/d for 10 days) alone or with an alternative deacetylating agent are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gene Silencing in Cancer in Association with Promoter Hypermethylation
Herman, J. G., & Baylin, S. B. (2003) · New England Journal of Medicine · doi:10.1056/nejmra023075 · Cited by 3,422
The Transcriptional Coactivators p300 and CBP Are Histone Acetyltransferases
Ogryzko, V. V., Schiltz, R. L., Russanova, V., Howard, B. H., & Nakatani, Y. (1996) · Cell · doi:10.1016/s0092-8674(00)82001-2 · Cited by 2,952
Cheson, B. D., Bennett, J. M., Kopecky, K. J., Büchner, T., Willman, C. L., Estey, E. H., Schiffer, C. A., Doehner, H., Tallman, M. S., Lister, T. A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.036 · Cited by 2,654
Creutzig, U., & Kaspers, G. J. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.99.116 · Cited by 2,137
Cameron, E. E., Bachman, K. E., Myöhänen, S., Herman, J. G., & Baylin, S. B. (1999) · Nature Genetics · doi:10.1038/5047 · Cited by 1,857
The CBP co-activator is a histone acetyltransferase
Bannister, A. J., & Kouzarides, T. (1996) · Nature · doi:10.1038/384641a0 · Cited by 1,805
Kantarjian, H., Issa, J. J., Rosenfeld, C. S., Bennett, J. M., Albitar, M., DiPersio, J., Klimek, V., Slack, J., de Castro, C., Ravandi, F., et al. (2006) · Cancer · doi:10.1002/cncr.21792 · Cited by 1,530
Kakizuka, A., Miller, W. H., Umesono, K., Warrell, R. P., Frankel, S. R., Murty, V. V. V. S., Dmitrovsky, E., & Evans, R. M. (1991) · Cell · doi:10.1016/0092-8674(91)90112-c · Cited by 1,427
Grignani, F., De Matteis, S., Nervi, C., Tomassoni, L., Gelmetti, V., Cioce, M., Fanelli, M., Ruthardt, M., Ferrara, F. F., Zamir, I., et al. (1998) · Nature · doi:10.1038/35901 · Cited by 1,004
Issa, J.-P. J., Garcia-Manero, G., Giles, F. J., Mannari, R., Thomas, D., Faderl, S., Bayar, E., Lyons, J., Rosenfeld, C. S., Cortes, J., et al. (2004) · Blood · doi:10.1182/blood-2003-03-0687 · Cited by 809
Kantarjian, H., Oki, Y., Garcia-Manero, G., Huang, X., O'Brien, S., Cortes, J., Faderl, S., Bueso-Ramos, C., Ravandi, F., Estrov, Z., et al. (2007) · Blood · doi:10.1182/blood-2006-05-021162 · Cited by 685
Gore, S. D., Baylin, S., Sugar, E., Carraway, H., Miller, C. B., Carducci, M., Grever, M., Galm, O., Dauses, T., Karp, J. E., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0080 · Cited by 474
Self-citationGarcia-Manero, G., Kantarjian, H. M., Sanchez-Gonzalez, B., Yang, H., Rosner, G., Verstovsek, S., Rytting, M., Wierda, W. G., Ravandi, F., Koller, C., et al. (2006) · Blood · doi:10.1182/blood-2006-03-009142 · Cited by 467
MLL: a histone methyltransferase disrupted in leukemia
Hess, J. L. (2004) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.08.005 · Cited by 360
Farag, S. S., Archer, K. J., Mrózek, K., Ruppert, A. S., Carroll, A. J., Vardiman, J. W., Pettenati, M. J., Baer, M. R., Qumsiyeh, M. B., Koduru, P. R., et al. (2006) · Blood · doi:10.1182/blood-2005-11-4354 · Cited by 334
Issa, J.-P. J., Gharibyan, V., Cortes, J., Jelinek, J., Morris, G., Verstovsek, S., Talpaz, M., Garcia-Manero, G., & Kantarjian, H. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.981 · Cited by 288
A Novel Fusion Between MOZ and the Nuclear Receptor Coactivator TIF2 in Acute Myeloid Leukemia
Carapeti, M., Aguiar, R. C. T., Goldman, J. M., & Cross, N. C. P. (1998) · Blood · doi:10.1182/blood.v91.9.3127 · Cited by 272
DNA Methylation Changes after 5-Aza-2′-Deoxycytidine Therapy in Patients with Leukemia
Yang, A. S., Doshi, K. D., Choi, S.-W., Mason, J. B., Mannari, R. K., Gharybian, V., Luna, R., Rashid, A., Shen, L., Estecio, M. R. H., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2385 · Cited by 266
Kuendgen, A., Strupp, C., Aivado, M., Bernhardt, A., Hildebrandt, B., Haas, R., Germing, U., & Gattermann, N. (2004) · Blood · doi:10.1182/blood-2003-12-4333 · Cited by 255
The corepressor CtBP interacts with Evi-1 to repress transforming growth factor β signaling
Izutsu, K., Kurokawa, M., Imai, Y., Maki, K., Mitani, K., & Hirai, H. (2001) · Blood · doi:10.1182/blood.v97.9.2815 · Cited by 229
Kuendgen, A., Schmid, M., Schlenk, R., Knipp, S., Hildebrandt, B., Steidl, C., Germing, U., Haas, R., Dohner, H., & Gattermann, N. (2006) · Cancer · doi:10.1002/cncr.21552 · Cited by 224
Chromatin Remodeling and Leukemia: New Therapeutic Paradigms
Redner, R. L., Wang, J., & Liu, J. M. (1999) · Blood · doi:10.1182/blood.v94.2.417 · Cited by 189
The role of MLL in hematopoiesis and leukemia
Ernst, P., Wang, J., & Korsmeyer, S. J. (2002) · Current Opinion in Hematology · doi:10.1097/00062752-200207000-00004 · Cited by 157
Whitman, S. P., Liu, S., Vukosavljevic, T., Rush, L. J., Yu, L., Liu, C., Klisovic, M. I., Maharry, K. S., Guimond, M., Strout, M. P., et al. (2005) · Blood · doi:10.1182/blood-2005-01-0204 · Cited by 153
Self-citationKlisovic, M. I., Maghraby, E. A., Parthun, M. R., Guimond, M., Sklenar, A. R., Whitman, S. P., Chan, K. K. L., Murphy, T., Anon, J., Archer, K. J., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2402776 · Cited by 142
Self-citationInterplay of RUNX1/MTG8 and DNA Methyltransferase 1 in Acute Myeloid Leukemia
Liu, S., Shen, T., Huynh, L., Klisovic, M. I., Rush, L. J., Ford, J. L., Yu, J., Becknell, B., Yu, L., Liu, C., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4532 · Cited by 142
Self-citationSingh, S. A., Unterberg, M., Koschmieder, S., Stadt, U. Z., Brunnberg, U., Verbeek, W., Büchner, T., Berdel, W. E., Serve, H. L., & Müller‐Tidow, C. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1681 · Cited by 110
Sundqvist, A., Sollerbrant, K., & Svensson, C. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)00588-2 · Cited by 107
Kurokawa, M., Mitani, K., Imai, Y., Ogawa, S., Yazaki, Y., & Hirai, H. (1998) · Blood · doi:10.1182/blood.v92.11.4003 · Cited by 105
Raval, A., Lucas, D. M., Matkovic, J. J., Bennett, K. L., Liyanarachchi, S., Young, D. C., Rassenti, L. Z., Kipps, T. J., Grever, M. R., Byrd, J. C., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.196 · Cited by 97
Self-citationLiu, Z., Marcucci, G., Byrd, J. C., Grever, M. R., Xiao, J. J., & Chan, K. K. (2006) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.2423 · Cited by 80
Self-citationEstrogen receptor methylation is associated with improved survival in adult acute myeloid leukemia.
Li, Q., Kopecky, K. J., MOHAN, A. L., Willman, C. L., Appelbaum, F. R., Weick, J. K., & Issa, J. J. (1999) · PubMed · Cited by 73
Liu, Z., Liu, S., Xie, Z., et al. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkl1156 · Cited by 72
Self-citationBrena, R. M. (2006) · Nucleic Acids Research · doi:10.1093/nar/gnj017 · Cited by 72
Molecular pathogenesis of acute promyelocytic leukaemia and APL variants
Sirulnik, A., Melnick, A., Zelent, A., & Licht, J. D. (2003) · Best Practice & Research Clinical Haematology · doi:10.1016/s1521-6926(03)00062-8 · Cited by 54
Cited by
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
Falkenberg, K. J., & Johnstone, R. W. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4360 · Cited by 1,564
Garzon, R., Liu, S., Fabbri, M., Liu, Z., Heaphy, C. E. A., Callegari, E., Schwind, S., Pang, J., Yu, J., Muthusamy, N., et al. (2009) · Blood · doi:10.1182/blood-2008-07-170589 · Cited by 781
Self-citationTsai, H.-C., Li, H., Van Neste, L., Cai, Y., Robert, C., Rassool, F. V., Shin, J. J., Harbom, K. M., Beaty, R., Pappou, E., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.12.029 · Cited by 650
Overcoming cancer therapeutic bottleneck by drug repurposing
Zhang, Z., Zhou, L., Xie, N., Nice, E. C., Zhang, T., Cui, Y., & Huang, C. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00213-8 · Cited by 516
Cashen, A. F., Schiller, G. J., O'Donnell, M. R., & DiPersio, J. F. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.9178 · Cited by 464
Metadata
- Authors
- Blum, W., Klisovic, R. B., Hackanson, B., Liu, Z., Liu, S., Devine, H., Vukosavljevic, T., Huynh, L., Lozanski, G., Kefauver, C., Plass, C., Devine, S. M., Heerema, N. A., Murgo, A., Chan, K. K., Grever, M. R., Byrd, J. C., & Marcucci, G.
- Venue
- Journal of Clinical Oncology
- Published
- 2007-09-01
- Volume
- 25
- Issue
- 25
- Pages
- 3884-3891
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1963919702
- Cited by
- 315
- References
- 35
- FWCI
- 15.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.